Arkansas Medicaid has settled a federal lawsuit brought by three cystic fibrosis (CF) patients who were denied the CF drug Kalydeco because of its high cost, according to a report by the Wall Street Journal‘s Joseph Walker. Kalydeco (generic name Ivacaftor) is an orally administered drug engineered…

Celtaxsys, Inc., a privately-owned, clinical stage drug discovery and development company focused on addressing serious inflammatory diseases, has just announced the U.S. Food and Drug Administration has granted the company’s experimental therapy CTX-4430 (oral leukotriene A4 hydrolase inhibitor) Orphan Drug Designation as a potential treatment…

Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company specializing in the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases, has just announced it has been invited to present at this week’s 17th Annual BIO CEO & Investor Conference. The conference, which will take place from February 9 to…

UK-based non-profit organization, Cystic Fibrosis Trust, recently launched a new awareness campaign that seeks to empower individuals living with cystic fibrosis (CF) to find out which specific CFTR gene mutation they are carrying. When patients know their specific mutation, physicians can prescribe more targeted, effective treatments, and even help patients participate in appropriate clinical…

In this week’s editorial column, Cystic Fibrosis News Today’s Stephen Shannon sounds off on the recent news of the Cystic Fibrosis Foundation‘s recent $3.3 billion royalty sale involving Vertex’s Kalydeco, the ensuing controversy over the deal in some corners of the media, and why he thinks the venture philanthropy model works. On…

An article published this week in the new edition of Annals of the American Thoracic Society, provides an essential overview of health indicators that are important to patients diagnosed with cystic fibrosis (CF). Study investigators from University of British Columbia, School of Population and Public…

A new report on cystic fibrosis (CF) in England and Wales further supports evidence of the groundbreaking impact that Kalydeco (ivacaftor) has had on treating CF, and reinforces the Cystic Fibrosis Trust‘s urgency for the drug to be made available to the 44 patients with rare CF gene mutations in…

During the annual meeting of the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR), medical device company Harmonica Techs asked health professionals dealing with cystic fibrosis and other pulmonary conditions if they observed that spirometry improves patients’ lung function through any of the standard interventions. In order to assess…

Cystic Fibrosis News Today is pleased to announce that Stephen Shannon, a student researcher currently earning his Ph.D. and a person with Cystic Fibrosis, will join the website’s editorial staff and publish a weekly column on his personal journey in living with the disease, as well as fresh insights…